Trastuzumab Deruxtecan (T-DXd): clinical trials recruiting now

Phase breakdown

Conditions being studied

Recruiting trials involving Trastuzumab Deruxtecan (T-DXd)

• A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
  NCT05824975 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 22 locations
• Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
  NCT05417594 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 130 Years · Sex: All (male and female) · 32 locations
• Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.
  NCT07407465 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 28 locations

Common questions

How many recruiting trials involve Trastuzumab Deruxtecan (T-DXd)?

3 recruiting trials across 15 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.